Pfizer agrees to allow other companies to make its COVID-19 pill
LONDON — Drugmaker Pfizer has signed a deal with a United Nations-backed group to let other manufacturers make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world’s population.
The move follows a similar decision by Merck, which has also developed a pill to treat people who come down with COVID-19.
In a statement Tuesday, Pfizer said it would grant a license for its antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the treatment pill for use in 95 countries, making up about 53% of the world’s population.
The deal excludes some large countries that have suffered devastating COVID-19 outbreaks. For example, while a Brazilian drug company could get a license to make the pill for export to other countries, the medicine could not be made generically for use in Brazil.
Still, health officials said the fact that the deal was struck even before Pfizer’s pill has been authorized anywhere could help to end the pandemic quicker.
“It’s quite significant that we will be able to provide access to a drug that appears to be effective and has just been developed to more than 4 billion people,” Esteban Burrone, head of policy at the Medicines Patent Pool, said.
Drugmaker Merck has asked U.S. regulators to authorize its promising pill protecting against COVID-19, setting the stage for a decision within weeks.
He predicted that other drugmakers would be able to start producing the pill within months, but acknowledged that the agreement wouldn’t please everyone.
“We try to strike a very delicate balance between the interests of the [company], the sustainability required by generic producers and, most importantly, the public-health needs in lower- and middle-income countries,” Burrone said.
Under the terms of the agreement, Pfizer will not receive royalties on sales in low-income countries and will waive royalties on sales in all countries covered by the agreement while COVID-19 remains a public health emergency.
Earlier this month, Pfizer said its pill cut the risk of hospitalization and death by nearly 90% in people with mild to moderate coronavirus infections. Independent experts recommended halting the company’s study early based on its promising results.
A new study found a cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19.
Pfizer said it would ask the U.S. Food and Drug Administration and other regulators to authorize the pill as soon as possible,
Since the pandemic erupted last year, researchers worldwide have raced to develop a pill to treat COVID-19 that can be taken at home to ease symptoms, speed recovery and keep people out of the hospital. At the moment, most COVID-19 treatments must be delivered intravenously or by injection.
Britain authorized Merck’s COVID-19 pill earlier this month, and it is pending approval elsewhere. In a similar deal with the Medicines Patent Pool announced in October, Merck agreed to let other drugmakers make its COVID-19 pill, molnupiravir, available in 105 poorer countries.
Doctors Without Borders said it was “disheartened” that the Pfizer deal does not make the drug available to the entire world, noting that the agreement announced Tuesday also excludes countries including China, Argentina and Thailand.
“The world knows by now that access to COVID-19 medical tools needs to be guaranteed for everyone, everywhere, if we really want to control this pandemic,” said Yuanqiong Hu, a senior legal policy advisor at Doctors Without Borders.
The decisions by Pfizer and Merck to share their COVID-19 drug patents stands in stark contrast to the refusal of Pfizer and other vaccine-makers to release their COVID-19 vaccine recipes for wider production. A hub set up by the World Health Organization in South Africa intended to share messenger RNA vaccine recipes and technologies has not enticed a single pharmaceutical to join.
Fewer than 1% of Pfizer’s COVID-19 shots have gone to poorer countries.
Sign up for Essential California
The most important California stories and recommendations in your inbox every morning.
You may occasionally receive promotional content from the Los Angeles Times.
